Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer

Siegel, 2015, Cancer statistics, 2015, CA Cancer J Clin, 65, 5, 10.3322/caac.21254 Rahib, 2014, Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, 74, 2913, 10.1158/0008-5472.CAN-14-0155 Gutt, 2010, The role of radiotherapy in locally advanced pancreatic carcinoma, Nat Rev Gastroenterol Hepatol, 7, 437, 10.1038/nrgastro.2010.98 Hidalgo, 2010, Pancreatic cancer, N Engl J Med, 362, 1605, 10.1056/NEJMra0901557 Oettle, 2007, Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial, J Am Med Assoc, 297, 267, 10.1001/jama.297.3.267 Sperti, 1997, Recurrence after resection for ductal adenocarcinoma of the pancreas, World J Surg, 21, 195, 10.1007/s002689900215 Westerdahl, 1993, Recurrence of exocrine pancreatic cancer—local or hepatic?, Hepatogastroenterol, 40, 384 Yeo CJ, Cameron JL, Sohn TA, et al: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 226:248-257; [discussion 257-260], 1997 Garcea, 2008, Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature, JOP, 9, 99 Kalser, 1985, Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection, Arch Surg, 120, 899, 10.1001/archsurg.1985.01390320023003 1987, Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group, Cancer, 59, 2006, 10.1002/1097-0142(19870615)59:12<2006::AID-CNCR2820591206>3.0.CO;2-B Klinkenbijl, 1999, Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group, Ann Surg, 230, 776, 10.1097/00000658-199912000-00006 Neoptolemos, 2001, Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial, Lancet, 358, 1576, 10.1016/S0140-6736(01)06651-X Neoptolemos, 2004, A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N Engl J Med, 350, 1200, 10.1056/NEJMoa032295 Neoptolemos, 2010, Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial, J Am Med Assoc, 304, 1073, 10.1001/jama.2010.1275 Regine, 2008, Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial, J Am Med Assoc, 299, 1019, 10.1001/jama.299.9.1019 Regine, 2011, Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial, Ann Surg Oncol, 18, 1319, 10.1245/s10434-011-1630-6 Corsini, 2008, Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005), J Clin Oncol, 26, 3511, 10.1200/JCO.2007.15.8782 Herman, 2008, Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital, J Clin Oncol, 26, 3503, 10.1200/JCO.2007.15.8469 Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 1817, 10.1056/NEJMoa1011923 Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, 369, 1691, 10.1056/NEJMoa1304369 Tempero, 2012, Pancreatic Adenocarcinoma, version 2.2012: Featured updates to the NCCN Guidelines, J Natl Compr Canc Netw, 10, 703, 10.6004/jnccn.2012.0073 Callery, 2009, Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement, Ann Surg Oncol, 16, 1727, 10.1245/s10434-009-0408-6 Katz, 2014, Management of borderline resectable pancreatic cancer, Semin Radiat Oncol, 24, 105, 10.1016/j.semradonc.2013.11.006 Ishikawa, 1991, Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreatoduodenectomy, Arch Surg, 126, 885, 10.1001/archsurg.1991.01410310095014 Mehta, 2001, Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas, J Gastrointest Surg, 5, 27, 10.1016/S1091-255X(01)80010-X Katz MH, Pisters PW, Evans DB, et al: Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg 206:833-846; [discussion 846-838], 2008 Esnaola, 2014, Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer, Int J Radiat Oncol Biol Phys, 88, 837, 10.1016/j.ijrobp.2013.12.030 Festa, 2013, Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: A meta-analytical evaluation of prospective studies, JOP, 14, 618 Kim, 2013, A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer, Cancer, 119, 2692, 10.1002/cncr.28117 Landry, 2010, Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma, J Surg Oncol, 101, 587, 10.1002/jso.21527 Van Buren, 2013, Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma, Ann Surg Oncol, 20, 3787, 10.1245/s10434-013-3161-9 Gillen, 2010, Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages, PLoS Med, 7, e1000267, 10.1371/journal.pmed.1000267 Varadhachary, 2008, Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head, J Clin Oncol, 26, 3487, 10.1200/JCO.2007.15.8642 Evans, 2008, Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head, J Clin Oncol, 26, 3496, 10.1200/JCO.2007.15.8634 Katz, 2012, Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators, Cancer, 118, 5749, 10.1002/cncr.27636 Katz, 2015, Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101, J Clin Oncol, 33, 4008, 10.1200/jco.2015.33.15_suppl.4008 Moertel, 1981, Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group, Cancer, 48, 1705, 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4 1988, Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group, J Natl Cancer Inst, 80, 751, 10.1093/jnci/80.10.751 Cohen, 2005, A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282, Int J Radiat Oncol Biol Phys, 62, 1345, 10.1016/j.ijrobp.2004.12.074 Klaassen, 1985, Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study, J Clin Oncol, 3, 373, 10.1200/JCO.1985.3.3.373 Wolff, 2001, Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma, Clin Cancer Res, 7, 2246 Okusaka, 2004, Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer, Br J Cancer, 91, 673, 10.1038/sj.bjc.6602001 Loehrer, 2011, Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial, J Clin Oncol, 29, 4105, 10.1200/JCO.2011.34.8904 Chauffert, 2008, Ann Oncol, 19, 1592, 10.1093/annonc/mdn281 Huguet, 2007, Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies, J Clin Oncol, 25, 326, 10.1200/JCO.2006.07.5663 Huguet, 2009, Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: A qualitative systematic review, J Clin Oncol, 27, 2269, 10.1200/JCO.2008.19.7921 Krishnan, 2007, Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy, Cancer, 110, 47, 10.1002/cncr.22735 Mukherjee, 2013, Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial, Lancet Oncol, 14, 317, 10.1016/S1470-2045(13)70021-4 Hammel, 2013, Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study, J Clin Oncol, 31, 10.1200/jco.2013.31.18_suppl.lba4003 Iacobuzio-Donahue, 2009, DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer, J Clin Oncol, 27, 1806, 10.1200/JCO.2008.17.7188 Crane, 2011, Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of SMAD4(Dpc4) immunostaining with pattern of disease progression, J Clin Oncol, 29, 3037, 10.1200/JCO.2010.33.8038 Bachet, 2012, Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma, Ann Oncol, 23, 2327, 10.1093/annonc/mdr617 Bachet, 2013, S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma, Eur J Cancer, 49, 2643, 10.1016/j.ejca.2013.04.017 Marechal, 2013, Towards a tailored therapy in pancreatic cancer, Acta Gastroenterol Belg, 76, 49 Ben-Josef, 2012, A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer, Int J Radiat Oncol Biol Phys, 84, 1166, 10.1016/j.ijrobp.2012.02.051 McGinn, 2001, Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer, J Clin Oncol, 19, 4202, 10.1200/JCO.2001.19.22.4202 Krishnan, 2016, Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation, Int J Radiat Oncol Biol Phys, 94, 755, 10.1016/j.ijrobp.2015.12.003 Huguet, 2012, Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations, Int J Radiat Oncol Biol Phys, 83, 1355, 10.1016/j.ijrobp.2011.11.050 Herman, 2015, Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma, Cancer, 121, 1128, 10.1002/cncr.29161 Li, 2004, Pancreatic cancer, Lancet, 363, 1049, 10.1016/S0140-6736(04)15841-8 Ferrara, 2004, Vascular endothelial growth factor: Basic science and clinical progress, Endocr Rev, 25, 581, 10.1210/er.2003-0027 Dvorak, 2002, Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, J Clin Oncol, 20, 4368, 10.1200/JCO.2002.10.088 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Gorski, 1999, Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation, Cancer Res, 59, 3374 Lee, 2000, Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions, Cancer Res, 60, 5565 Crane, 2006, Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer, J Clin Oncol, 24, 1145, 10.1200/JCO.2005.03.6780 Crane, 2009, Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411, J Clin Oncol, 27, 4096, 10.1200/JCO.2009.21.8529 Small, 2011, Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer, Int J Radiat Oncol Biol Phys, 80, 476, 10.1016/j.ijrobp.2010.02.030 Varadhachary, 2008, Preoperative gemcitabine (gem) and bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma, J Clin Oncol, 26, 4630, 10.1200/jco.2008.26.15_suppl.4630 MacKenzie, 2004, Molecular therapy in pancreatic adenocarcinoma, Lancet Oncol, 5, 541, 10.1016/S1470-2045(04)01565-7 Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, 351, 337, 10.1056/NEJMoa033025 Xiong, 2004, Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II Trial, J Clin Oncol, 22, 2610, 10.1200/JCO.2004.12.040 Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 25, 1960, 10.1200/JCO.2006.07.9525 Herman, 2013, Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer, Int J Radiat Oncol Biol Phys, 86, 678, 10.1016/j.ijrobp.2013.03.032 Duffy, 2008, A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma, Ann Oncol, 19, 86, 10.1093/annonc/mdm441 Williams, 2002, ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model, Br J Cancer, 86, 1157, 10.1038/sj.bjc.6600182 Raben, 2002, ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer, Semin Oncol, 29, 37, 10.1053/sonc.2002.31521 Czito, 2006, Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results, J Clin Oncol, 24, 656, 10.1200/JCO.2005.04.1749 Stromnes, 2014, Stromal reengineering to treat pancreas cancer, Carcinogenesis, 35, 1451, 10.1093/carcin/bgu115 Rucki, 2014, Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies, World J Gastroenterol, 20, 2237, 10.3748/wjg.v20.i9.2237 Maitra, 2008, Pancreatic cancer, Annu Rev Pathol, 3, 157, 10.1146/annurev.pathmechdis.3.121806.154305 Hwang, 2008, Cancer-associated stromal fibroblasts promote pancreatic tumor progression, Cancer Res, 68, 918, 10.1158/0008-5472.CAN-07-5714 Garrido-Laguna, 2011, Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer, Clin Cancer Res, 17, 5793, 10.1158/1078-0432.CCR-11-0341 Yauch, 2008, A paracrine requirement for hedgehog signalling in cancer, Nature, 455, 406, 10.1038/nature07275 Ijichi, 2011, Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma, J Clin Invest, 121, 4106, 10.1172/JCI42754 Thayer, 2003, Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis, Nature, 425, 851, 10.1038/nature02009 Olive, 2009, Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer, Science, 324, 1457, 10.1126/science.1171362 Madden JI: Infinity Reports Update from Phase 2 Study of Saridegib Plus Gemcitabine in Patients with Metastatic Pancreatic Cancer, 2012 Ko, 2016, A phase I study of FOLFIRINOX Plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma, Pancreas, 45, 370, 10.1097/MPA.0000000000000458 Catenacci, 2015, Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer, J Clin Oncol, 33, 4284, 10.1200/JCO.2015.62.8719 Provenzano, 2012, Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma, Cancer Cell, 21, 418, 10.1016/j.ccr.2012.01.007 Cascinu, 2006, New target therapies in advanced pancreatic cancer, Ann Oncol, 17, v148, 10.1093/annonc/mdj971 Evans, 2001, A phase II trial of marimastat in advanced pancreatic cancer, Br J Cancer, 85, 1865, 10.1054/bjoc.2001.2168 Moore, 2003, Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12–9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 21, 3296, 10.1200/JCO.2003.02.098 Almoguera, 1988, Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, Cell, 53, 549, 10.1016/0092-8674(88)90571-5 Infante, 2014, A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas, Eur J Cancer, 50, 2072, 10.1016/j.ejca.2014.04.024 Van Cutsem, 2015, Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer, J Clin Oncol, 33, 10.1200/jco.2015.33.3_suppl.344 Lowery, 2015, Novel therapeutics for pancreatic adenocarcinoma, Hematol Oncol Clin North Am, 29, 777, 10.1016/j.hoc.2015.04.006 Denley, 2013, Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma, J Gastrointest Surg, 17, 887, 10.1007/s11605-013-2168-7 Hurwitz, 2015, Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed, J Clin Oncol, 4039, 10.1200/JCO.2015.61.4578 Li, 2007, Identification of pancreatic cancer stem cells, Cancer Res, 67, 1030, 10.1158/0008-5472.CAN-06-2030 Rasheed, 2010, Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma, J Natl Cancer Inst, 102, 340, 10.1093/jnci/djp535 Jimeno, 2009, A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development, Mol Cancer Ther, 8, 310, 10.1158/1535-7163.MCT-08-0924 Rajeshkumar, 2010, A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model, Mol Cancer Ther, 9, 2582, 10.1158/1535-7163.MCT-10-0370 O′Reilly, 2014, Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC), J Clin Oncol, 32 Wolpin, 2014, Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma, Oncologist, 19, 637, 10.1634/theoncologist.2014-0086 Sun, 2012, Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer, Clin Cancer Res, 18, 758, 10.1158/1078-0432.CCR-11-1980 Borad, 2015, Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer, J Clin Oncol, 33, 1475, 10.1200/JCO.2014.55.7504 Phillips, 2007, Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70, Cancer Res, 67, 9407, 10.1158/0008-5472.CAN-07-1077 Chugh, 2012, A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer, Sci Transl Med, 4, 156ra139, 10.1126/scitranslmed.3004334 Banerjee, 2015, Minnelide, a novel drug for pancreatic and liver cancer, Pancreatology, 15, S39, 10.1016/j.pan.2015.05.472 Wang, 2007, Enhanced antitumor effect of combined triptolide and ionizing radiation, Clin Cancer Res, 13, 4891, 10.1158/1078-0432.CCR-07-0416 Banerjee, 2016, Impaired synthesis of stromal components in response to minnelide improves vascular function, drug delivery, and survival in pancreatic cancer, Clin Cancer Res, 22, 415, 10.1158/1078-0432.CCR-15-1155 Chadha AS, Skinner HD, Gunther JR, et al: Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS ONE 11: e0156910, 2016. Wormann, 2014, The immune network in pancreatic cancer development and progression, Oncogene, 33, 2956, 10.1038/onc.2013.257 Melero, 2013, Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination, Clin Cancer Res, 19, 997, 10.1158/1078-0432.CCR-12-2214 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694 Nomi, 2007, Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer, Clin Cancer Res, 13, 2151, 10.1158/1078-0432.CCR-06-2746 Wang, 2010, Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma, World J Surg, 34, 1059, 10.1007/s00268-010-0448-x Tykodi, 2012, PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors, J Clin Oncol, 30 Korman, 2006, Checkpoint blockade in cancer immunotherapy, Adv Immunol, 90, 297, 10.1016/S0065-2776(06)90008-X Royal, 2010, Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma, J Immunother, 33, 828, 10.1097/CJI.0b013e3181eec14c Beatty, 2011, CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans, Science, 331, 1612, 10.1126/science.1198443 Beatty, 2013, A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma, Clin Cancer Res, 19, 6286, 10.1158/1078-0432.CCR-13-1320 Fokas, 2015, Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic, Biochim Biophys Acta, 1855, 61 Maliar A, Servais C, Waks T, et al: Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 143(1375-1384.e1371-1375), 2012 Zhao, 2010, Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor, Cancer Res, 70, 9053, 10.1158/0008-5472.CAN-10-2880 Maus, 2013, T cells expressing chimeric antigen receptors can cause anaphylaxis in humans, Cancer Immunol Res, 1, 26, 10.1158/2326-6066.CIR-13-0006 Mellor, 2003, Cutting edge: Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion, J Immunol, 171, 1652, 10.4049/jimmunol.171.4.1652 Godin-Ethier, 2011, Indoleamine 2,3-dioxygenase expression in human cancers: Clinical and immunologic perspectives, Clin Cancer Res, 17, 6985, 10.1158/1078-0432.CCR-11-1331 Muller, 2005, Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy, Nat Med, 11, 312, 10.1038/nm1196 Laheru, 2008, Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation, Clin Cancer Res, 14, 1455, 10.1158/1078-0432.CCR-07-0371 Jaffee, 1998, Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials, Cancer J Sci Am, 4, 194 Thomas, 1998, Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine, Hum Gene Ther, 9, 835, 10.1089/hum.1998.9.6-835 Jaffee, 2001, Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation, J Clin Oncol, 19, 145, 10.1200/JCO.2001.19.1.145 Lutz, 2014, Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation, Cancer Immunol Res, 2, 616, 10.1158/2326-6066.CIR-14-0027 Le, 2013, Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer, J Immunother, 36, 382, 10.1097/CJI.0b013e31829fb7a2 Ercolini, 2005, Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response, J Exp Med, 201, 1591, 10.1084/jem.20042167 Le, 2012, A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction, Clin Cancer Res, 18, 858, 10.1158/1078-0432.CCR-11-2121 Aguilar, 2011, Cytotoxic immunotherapy strategies for cancer: Mechanisms and clinical development, J Cell Biochem, 112, 1969, 10.1002/jcb.23126 Hardacre, 2013, Addition of algenpantucel-l immunotherapy to standard adjuvant therapy for pancreatic cancer: A phase 2 study, J Gastrointest Surg, 17, 94, 10.1007/s11605-012-2064-6 Middleton, 2014, Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial, Lancet Oncol, 15, 829, 10.1016/S1470-2045(14)70236-0 Weden, 2011, Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras, Int J Cancer, 128, 1120, 10.1002/ijc.25449 Lepisto, 2008, A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors, Cancer Ther, 6, 955 Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368 Liu, 2014, Gene therapy in pancreatic cancer, World J Gastroenterol, 20, 13343, 10.3748/wjg.v20.i37.13343 Hecht, 2003, A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma, Clin Cancer Res, 9, 555 Etoh, 2003, Oncolytic viral therapy for human pancreatic cancer cells by reovirus, Clin Cancer Res, 9, 1218 Zhang, 2003, p14ARF upregulation of p53 and enhanced effects of 5-fluorouracil in pancreatic cancer, Chin Med J, 116, 1150 Liu, 2011, Multiple treatment cycles of liposome-encapsulated adenoviral RIP-TK gene therapy effectively ablate human pancreatic cancer cells in SCID mice, Surgery, 149, 484, 10.1016/j.surg.2010.11.014 Buscail, 2015, First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: Safety, biodistribution, and preliminary clinical findings, Mol Ther, 23, 779, 10.1038/mt.2015.1 Gupta, 2010, Influence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells, Pancreatology, 10, 565, 10.1159/000317254 Li, 2013, Recombinant adenovirus-p53 (Gendicine) sensitizes a pancreatic carcinoma cell line to radiation, Chin J Cancer Res, 25, 715 Hwang RF, Gordon EM, Anderson WF, et al: Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery 124:143-150; [discussion 150-141], 1998 Hasei, 2013, Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells, Mol Cancer Ther, 12, 314, 10.1158/1535-7163.MCT-12-0869 Nemunaitis, 2009, Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck, Clin Cancer Res, 15, 7719, 10.1158/1078-0432.CCR-09-1044 Shen, 2008, Inhibition of pancreatic carcinoma cell growth in vitro by DPC4 gene transfection, World J Gastroenterol, 14, 6254, 10.3748/wjg.14.6254 Duda, 2003, Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells, Oncogene, 22, 6857, 10.1038/sj.onc.1206751 Buchler, 2003, Pancreatic cancer growth is inhibited by blockade of VEGF-RII, Surgery, 134, 772, 10.1016/S0039-6060(03)00296-4 Reinblatt, 2005, Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma, Ann Surg Oncol, 12, 1025, 10.1245/ASO.2005.03.081 Vachutinsky, 2011, Antiangiogenic gene therapy of experimental pancreatic tumor by sFlt-1 plasmid DNA carried by RGD-modified crosslinked polyplex micelles, J Control Release, 149, 51, 10.1016/j.jconrel.2010.02.002 Ogawa, 2002, Anti-tumor angiogenesis therapy using soluble receptors: Enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor, Cancer Gene Ther, 9, 633, 10.1038/sj.cgt.7700478 Nie, 2002, Experimental study of gene therapy with angiostatin gene in pancreatic cancer, Hepatobiliary Pancreat Dis Int, 1, 452 Li, 2006, Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice, Gut, 55, 259, 10.1136/gut.2005.064980 Tysome, 2009, Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer, Gene Ther, 16, 1223, 10.1038/gt.2009.74 Rigg, 2001, Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo, Cancer Gene Ther, 8, 869, 10.1038/sj.cgt.7700387 Bloomston, 2002, TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis, J Surg Res, 102, 39, 10.1006/jsre.2001.6318 Carrio, 1999, Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene, Gene Ther, 6, 547, 10.1038/sj.gt.3300846 Aoki, 1997, Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene, Hum Gene Ther, 8, 1105, 10.1089/hum.1997.8.9-1105 Evoy, 1997, In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer, J Surg Res, 69, 226, 10.1006/jsre.1997.5051 Kaliberova, 2008, Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene, Mol Cancer Ther, 7, 2845, 10.1158/1535-7163.MCT-08-0347 Erbs, 2000, In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene, Cancer Res, 60, 3813 Carrio, 2002, Intratumoral activation of cyclophosphamide by retroviral transfer of the cytochrome P450 2B1 in a pancreatic tumor model. Combination with the HSVtk/GCV system, J Gene Med, 4, 141, 10.1002/jgm.247 Lohr, 1998, Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450, Gene Ther, 5, 1070, 10.1038/sj.gt.3300671 Lohr, 2001, Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma, Lancet, 357, 1591, 10.1016/S0140-6736(00)04749-8 Kimura, 1998, Loss of tumorigenicity of human pancreatic carcinoma cells engineered to produce interleukin-2 or interleukin-4 in nude mice: A potentiality for cancer gene therapy, Cancer Lett, 128, 47, 10.1016/S0304-3835(98)00050-0 Xie, 2013, Adenovirus-mediated interferon-gamma gene therapy induced human pancreatic carcinoma Capan-2 cell apoptosis in vitro and in vivo, Anat Rec, 296, 604, 10.1002/ar.22661 Poutou, 2015, Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model, Gene Ther, 22, 696, 10.1038/gt.2015.45 Endou, 2005, Growth inhibition of human pancreatic cancer cells by human interferon-beta gene combined with gemcitabine, Int J Mol Med, 15, 277 Murugesan, 2009, Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer, Cancer Gene Ther, 16, 841, 10.1038/cgt.2009.32 Herman, 2013, Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: Final results, J Clin Oncol, 31, 886, 10.1200/JCO.2012.44.7516 Kashani-Sabet, 2002, Ribozyme therapeutics, J Invest Dermatol, 7, 76, 10.1046/j.1523-1747.2002.19642.x Brummelkamp, 2002, Stable suppression of tumorigenicity by virus-mediated RNA interference, Cancer Cell, 2, 243, 10.1016/S1535-6108(02)00122-8 Miura, 2005, Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity, Cancer Lett, 218, 53, 10.1016/j.canlet.2004.08.015 Morioka, 2005, Suppression of invasion of a hamster pancreatic cancer cell line by antisense oligonucleotides mutation-matched to K-ras gene, In Vivo, 19, 535 Yan, 2006, Bystander effect contributes to the antitumor efficacy of CaSm antisense gene therapy in a preclinical model of advanced pancreatic cancer, Mol Ther, 13, 357, 10.1016/j.ymthe.2005.06.485 Golan, 2013, A phase I trial of a local delivery of siRNA against k-ras in combination with chemotherapy for locally advanced pancreatic adenocarcinoma, J Clin Oncol, 31, 10.1200/jco.2013.31.15_suppl.4037 Alberts, 2004, Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group phase II trial, J Clin Oncol, 22, 4944, 10.1200/JCO.2004.05.034 Russell, 2012, Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest, Oncogene, 31, 2450, 10.1038/onc.2011.431 Gordon, 2001, Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice, Hum Gene Ther, 12, 193, 10.1089/104303401750061258 Gordon, 2004, First clinical experience using a ‘pathotropic’ injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer, Int J Oncol, 24, 177 Chawla, 2010, Advanced phase I/II studies of targeted gene delivery in vivo: Intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer, Mol Ther, 18, 435, 10.1038/mt.2009.228 Wang, 2006, Inhibitory effects of antisense phosphorothioate oligodeoxynucleotides on pancreatic cancer cell Bxpc-3 telomerase activity and cell growth in vitro, World J Gastroenterol, 12, 4004, 10.3748/wjg.v12.i25.4004 Liu, 2009, Antitumor efficacy of human telomerase reverse transcriptase gene antisense oligonucleotide in pancreatic cancer cells, Mol Med Rep, 2, 515 Hayashidani, 2005, Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells, Hiroshima J Med Sci, 54, 21 Zhong, 2010, Knockdown of hTERT by SiRNA suppresses growth of Capan-2 human pancreatic cancer cell via the inhibition of expressions of Bcl-2 and COX-2, J Dig Dis, 11, 176, 10.1111/j.1751-2980.2010.00433.x Pittella, 2012, Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate/charge-conversional polymer hybrid nanoparticles, J Control Release, 161, 868, 10.1016/j.jconrel.2012.05.005 Hotz, 2005, VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer, Surgery, 137, 192, 10.1016/j.surg.2004.07.015 Rosenberger, 2015, Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer, J Control Release, 214, 76, 10.1016/j.jconrel.2015.07.017 Park, 2015, Super paramagnetic nanoparticles for the diagnostic imaging of pancreatic cancer, J Control Release, 214, 134, 10.1016/j.jconrel.2015.08.020 Hahn, 2011, Nanoparticles as contrast agents for in-vivo bioimaging: Current status and future perspectives, Anal Bioanal Chem, 399, 3, 10.1007/s00216-010-4207-5 Melo, 2015, Glypican-1 identifies cancer exosomes and detects early pancreatic cancer, Nature, 523, 177, 10.1038/nature14581 Kelley, 2014, Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering, Nat Nanotechnol, 9, 969, 10.1038/nnano.2014.261 Frese, 2012, nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer, Cancer Discov, 2, 260, 10.1158/2159-8290.CD-11-0242 Arsawang, 2011, How do carbon nanotubes serve as carriers for gemcitabine transport in a drug delivery system?, J Mol Graph Model, 29, 591, 10.1016/j.jmgm.2010.11.002 Stacey, 2011, Nanosecond pulse electrical fields used in conjunction with multi-wall carbon nanotubes as a potential tumor treatment, Biomed Mater, 6, 011002, 10.1088/1748-6041/6/1/011002 Patra, 2008, Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent, Cancer Res, 68, 1970, 10.1158/0008-5472.CAN-07-6102 Kudgus, 2013, Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics, PloS One, 8, e57522, 10.1371/journal.pone.0057522 Meng, 2015, Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice, ACS Nano, 9, 3540, 10.1021/acsnano.5b00510 Jaidev, 2015, Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy, Mater Sci Eng C Mater Biol Appl, 47, 40, 10.1016/j.msec.2014.11.027 Aggarwal, 2011, EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer, J Biomed Nanotechnol, 7, 137, 10.1166/jbn.2011.1238 David, 2015, Dual drug loaded chitosan nanoparticles-sugar-coated arsenal against pancreatic cancer, Colloids Surf B Biointerfaces, 135, 689, 10.1016/j.colsurfb.2015.08.038 Yalcin, 2014, Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines, Biomed Pharmacother, 68, 737, 10.1016/j.biopha.2014.07.003 Zhao, 2015, Co-delivery of HIF1 alpha siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer, Biomaterials, 46, 13, 10.1016/j.biomaterials.2014.12.028 Yamamoto, 2015, Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models, Cancer Sci, 106, 627, 10.1111/cas.12645 Zhou, 2015, IGF1 receptor targeted theranostic nanoparticles for targeted and image-guided therapy of pancreatic cancer, ACS Nano, 9, 7976, 10.1021/acsnano.5b01288 Coelho, 2015, Functionalized gold nanoparticles improve afatinib delivery into cancer cells, Expert Opin Drug Deliv, 1 Khan, 2015, Nanoparticle formulation of ormeloxifene for pancreatic cancer, Biomaterials, 53, 731, 10.1016/j.biomaterials.2015.02.082 Thakkar, 2015, Evaluation of ibuprofen loaded solid lipid nanoparticles and its combination regimens for pancreatic cancer chemoprevention, Int J Oncol, 46, 1827, 10.3892/ijo.2015.2879 Braga, 2015, Molecular confinement of human amylin in lipidic nanoparticles, J Liposome Res, 1 Kesharwani, 2015, Parenterally administrable nano-micelles of 3,4-difluorobenzylidene curcumin for treating pancreatic cancer, Colloids Surf B Biointerfaces, 132, 138, 10.1016/j.colsurfb.2015.05.007 Shen, 2015, Preparation of a thermosensitive gel composed of a mPEG-PLGA-PLL-cRGD nanodrug delivery system for pancreatic tumor therapy, ACS Appl Mater Interfaces, 7, 20530, 10.1021/acsami.5b06043 Drummond, 2006, Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy, Cancer Res, 66, 3271, 10.1158/0008-5472.CAN-05-4007 Von Hoff, 2013, NAPOLI 1: Randomized phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy, Br J Cancer, 109, 920 Yi, 2009, Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer, Cancer Chemother Pharmacol, 63, 1141, 10.1007/s00280-008-0839-y Chen, 2014, Targeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells, Nanomed, 9, 1209, 10.2217/nnm.13.84 Mocan, 2011, Selective ex-vivo photothermal ablation of human pancreatic cancer with albumin functionalized multiwalled carbon nanotubes, Int J Nanomed, 6, 915 Roesch, 2015, Review: The role of hyperthermia in treating pancreatic tumors, Indian J Surg Oncol, 6, 75, 10.1007/s13193-014-0316-5 Basel, 2012, Cell-delivered magnetic nanoparticles caused hyperthermia-mediated increased survival in a murine pancreatic cancer model, Int J Nanomedicine, 7, 297, 10.2147/IJN.S28344 Hainfeld, 2008, Radiotherapy enhancement with gold nanoparticles, J Pharm Pharmacol, 60, 977, 10.1211/jpp.60.8.0005 Schuemann, 2016, Roadmap to clinical use of gold nanoparticles for radiation sensitization, Int J Radiat Oncol Biol Phys, 94, 189, 10.1016/j.ijrobp.2015.09.032 Chatterjee, 2013, Convergence of nanotechnology with radiation therapy-insights and implications for clinical translation, Transl Cancer Res, 2, 256 Hainfeld, 2004, The use of gold nanoparticles to enhance radiotherapy in mice, Phys Med Biol, 49, N309, 10.1088/0031-9155/49/18/N03 Kunjachan, 2015, Nanoparticle mediated tumor vascular disruption: A novel strategy in radiation therapy, Nano Lett, 15, 7488, 10.1021/acs.nanolett.5b03073